Novo Nordisk's pill is selling. Whether that is enough to catch Eli Lilly is another matter.
For a company that not so long ago was the most valuable in Europe, Novo Nordisk has spent the past year looking unusually mortal. Its share price has shed 30% over twelve months. Its forecasts have been cut. Its American arch-rival, Eli Lilly, has gobbled up the headlines, the prescriptions and the patience of investors. So when the Danish drugmaker announced on May 6th that it was raising both its sales and profit guidance for the year, the market reaction — a 7.5% jump in early trading — looked less like vindication than relief.
The cause for cheer is a small white tablet called Wegovy. Approved by America's Food and Drug Administration in December and on sale a month later, the oral version of Novo's blockbuster injectable racked up 1.3m prescriptions in the first quarter and more than 2m by mid-April. That is enough to persuade Novo's bosses that this year's sales will fall by 4% to 12%, rather than the 13% drop they warned of in February. Operating profit, previously expected to slump by 13%, is now forecast within the same milder range. First-quarter adjusted operating profit came in at DKr32.86bn ($5.15bn), down 6% in constant currencies but ahead of analysts' expectations.
The rest of the picture is less straightforward. Headline sales of DKr96.8bn included a one-off DKr26.8bn payment tied to a long-running dispute over the company's participation in an American discount-drug programme, settled in January. Strip that out, and adjusted sales fell by 4%. Weight-loss product sales rose 22%, but overall company revenue still slipped because Novo has been forced to cut prices to keep up with Lilly. Volume is up; value is harder.
Novo's predicament illustrates a peculiar feature of the obesity-drug boom. The market is enormous, the demand near-bottomless and the molecules genuinely transformative — and yet, in commercial terms, the rewards have flowed disproportionately to the firm that arrived second. Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, has steadily eroded Novo's first-mover advantage, helped by data suggesting it produces somewhat greater weight loss than semaglutide. Lilly's pill, Foundayo, was cleared by the FDA last month, threatening to chip away at the only segment of the market in which Novo has had a clear lead.
That competitive picture explains why investors greeted Wednesday's results with something closer to grateful surprise than enthusiasm. Novo has the larger oral franchise, for now. But the broader question — whether the company can mount a credible defence of its position in obesity, deepen its pipeline and respond to American pricing pressure under a second Trump administration that has linked domestic drug prices to those paid in Europe — remains unresolved. The firm's pipeline, in particular, has come in for sceptical scrutiny. After CagriSema, an experimental combination drug, produced disappointing trial results last year, the well of next-generation candidates has begun to look shallower than its boosters once claimed.
A more existential question hovers behind the quarterly numbers. Novo Nordisk built its modern fortune on a single therapeutic class: GLP-1 receptor agonists, a family of molecules whose biology it pioneered and whose commercial potential it spent two decades quietly cultivating. That bet has paid off spectacularly. But it has also left the company unusually concentrated in a market that is now drawing in every large pharmaceutical group with the capital to compete. Pfizer, Roche, AstraZeneca and a clutch of Chinese biotechs are all developing rival programmes. Lilly, meanwhile, has the broader portfolio, the cash flow and — increasingly — the momentum.
Wednesday's pill-driven upgrade thus tells investors something true and something they already feared. Wegovy in tablet form is selling well enough to provide the company with a near-term cushion against a difficult year. But cushions are not catalysts. For Novo Nordisk to recapture the swagger of its recent past, it will need more than a clever reformulation of an existing molecule. It will need to prove, against a determined American rival, that it can still innovate at the pace its valuation once assumed. The market, judging by the tepid enthusiasm beneath Wednesday's bounce, is not yet convinced.